深耕心血管疾病精准诊疗领域 北芯生命(688712.SH)拟公开发行5700万股

Group 1 - The company, Beixin Life (688712.SH), plans to publicly issue 57 million shares, accounting for 13.67% of the total share capital after the issuance [1] - The initial strategic placement will involve 11.4 million shares, representing 20% of the total issuance, with senior management and core employees participating in a special asset management plan for 5.7 million shares, which is 10% of the total issuance [1] - The initial strategic placement by the sponsoring institution, China International Capital Corporation Wealth Securities Co., Ltd., is expected to be 2.85 million shares, or 5% of the total issuance, with a subscription amount not exceeding 40 million yuan [1] Group 2 - The company focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, being a national high-tech enterprise [2] - Its core products include the intravascular ultrasound (IVUS) diagnostic system and the fractional flow reserve (FFR) measurement system, both of which are the first domestically approved products in China [2] - The company reported net profits attributable to the parent company of -290 million yuan, -140 million yuan, -43.596 million yuan, and 49.4496 million yuan for the years 2022 to the first half of 2025, with an expected profit of 78 million to 88 million yuan for 2025, representing a growth of 278.91% to 301.85% year-on-year [2] - The total planned investment from the raised funds, after deducting issuance costs, is 952 million yuan, allocated to the construction of an interventional medical device industrialization base, R&D projects, and working capital [2]